Sarepta says FDA delays decision on muscle-wasting disorder drug

(Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had delayed a decision on its lead drug for a rare muscle-wasting disorder.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro